Gut bacteria change to help immunotherapy for liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether changing the bacteria in your gut (with a probiotic) can help your current immunotherapy work better if your liver cancer has been growing. It's for people with advanced liver cancer who will continue their same immunotherapy despite the cancer progressing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced liver cancer that cannot be removed by surgery
- Your cancer got worse while on standard first-line immunotherapy, but your doctor wants you to stay on that same treatment
- Your liver function is good (Child-Pugh class A) and you are up and active (ECOG 0 or 1)
- You are 18 or older and willing to take a probiotic capsule
- You do not have serious other health issues like uncontrolled infections, autoimmune disease, or recent major surgery
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how the gut (your digestive system) affects how well immunotherapy works for advanced liver cancer. You'll have a colonoscopy (a test to look inside your bowel) and provide samples, which could help doctors improve treatment for you and others.
This study is testing whether combining targeted therapy with immunotherapy (or using two immunotherapies together) can help people with liver cancer that cannot be surgically removed. The goal is to understand how well these treatments work and how they affect biomarkers (signals in your body that show treatment response).
This trial studies how liver cancer changes during immunotherapy and looks for biological markers that may predict treatment response. It helps doctors understand why some patients benefit more from treatment.
This trial aims to discover new immune system targets on liver cancer cells and other tumors to develop better immunotherapies. Researchers will analyze tumor samples to find these targets, which could lead to more effective treatments.
This trial tests immunotherapy-based combinations for liver cancer. It may help if your doctor thinks this treatment could benefit you.
This trial tests a combination of immunotherapy (anti-PD-1/PD-L1) and an anti-VEGF drug for people with advanced hepatocellular carcinoma (HCC), a type of liver cancer that cannot be removed by surgery or has spread. The goal is to see if these drugs can shrink tumors or slow the cancer's growth.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.